At the ASCO meeting in 2021, Lepu Biopharma reported on the progress of two clinical studies of HX008. The first study is second or later line treatment of advanced melanoma with HX008. The overall response rate (ORR） of HX008 in the treatment of advanced melanoma (199 patients) is 18.49%, the disease control rate (DCR）is 44.54%, the median progression-free survival (mPFS) is 3.25 months, and the median overall survival (mOS) is 17.91 months.

The second study is a phase II clinical study on the second or later line treatment of advanced solid tumors of MSI-H / dMMR with HX008. The ORR of HX008 in the treatment of dMMR solid tumors ((86 patients)  is 47.67%, the DCR is 75.58%, As of the cutoff date, the mPFS has yet to reach, and the 12-month PFS rate is 52.70%.

It is anticipated that HX008 will continue the clinical trials and gain marketing approval to benefit cancer patients in the near future.  

Source from PharmNote